Henagliflozin is named as a drug or biological intervention in 3 clinical trials in our China trial register, none of which are currently recruiting. Lead sponsors include Shandong Provincial Hospital (1), Xiqiao Zhou (1) and Shanghai East Hospital (1). Registered phases: Phase 4 and Not applicable. Conditions studied include PreDiabetes; Prediabetic State; Type 2 Diabetes.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06448130 | Henagliflozin's Impact on Prediabetes Remission (ClinicalTrials.gov ↗) PreDiabetes, Prediabetic State, Type 2 Diabetes |
Phase 4 | Not yet open |
| NCT06762223 | Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM (ClinicalTrials.gov ↗) Metabolic Dysfunction-associated Steatotic Liver Disease, Type 2 Diabetes Mellitus |
Phase 4 | Not yet open |
| NCT07294495 | Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR (ClinicalTrials.gov ↗) HCM - Hypertrophic Cardiomyopathy |
Not applicable | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| PreDiabetes | 1 |
| Prediabetic State | 1 |
| Type 2 Diabetes | 1 |
| Glucose Metabolism Disorders | 1 |
| Metabolic Dysfunction-associated Steatotic Liver Disease | 1 |
| Type 2 Diabetes Mellitus | 1 |
| HCM - Hypertrophic Cardiomyopathy | 1 |
| Lead sponsor | Trials |
|---|---|
| Shandong Provincial Hospital | 1 |
| Xiqiao Zhou | 1 |
| Shanghai East Hospital | 1 |
| Register | Henagliflozin trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Henagliflozin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Henagliflozin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.